Partnering, licensing, and collaboration are essential to our business and the end-goal of all our commercialization efforts. We depend on these activities to create lasting and growing value from our proven innovation. To this end Micropharma has focused significant resources to build a team, process, and company to make these relationships successful.
Micropharma is always interested in building new relationships, growing existing ones, and working with interested, qualified investors who would like be part of our growing company.
March 11, 2014
Micropharma and UAS Lifesciences were bestowed NEXT Innovation Summits NutrAwards for Best New Ingredient and Finished Product. The NutrAward for best new functional ingredient was presented to Micropharma for its probiotic Lactobacillus reuteri NCIMB 30242. This exciting probiotic, Lactobacillus reuteri NCIMB 30242, has the property of lowering cholesterol levels as well as additional cardiovascular and metabolic benefits.
February 24, 2014
Micropharma's cholesterol lowering probiotic Lactobacillus reuteri NCIMB 30242 was chosen as one of three finalists for the NutrAward for Best New Ingredient of 2014. Now in its 16th year, the NutrAward recognizes and rewards ingredient suppliers that have ingredients with scientific merit, efficacy, market potential, safety, innovation and the ability to increase market credibility. This year's NutrAward finalists were culled from scores of ingredient nominations and more than 100 entrants by our juried panel of industry experts, scientists and nutritionists.